Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility Study of the Use of Intermediate Doses of Cytarabine Associated With Autologous Hematopoietic Stem Cells as Consolidation Treatment of Young Adults With Low- or Intermediate-risk de Novo Acute Myeloid Leukemia

NCT03023384 is registered in ClinicalTrials.gov with International Consortium on Acute Leukemias as lead sponsor.

NCT NCT03023384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03023384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility Study of the Use of Intermediate Doses of Cytarabine Associated With Autologous Hematopoietic Stem Cells as Consolidation Treatment of Young Adults With Low- or Intermediate-risk de Novo Acute Myeloid Leukemia
Lead sponsor
International Consortium on Acute Leukemias
Phase
Observational
Overall status
Unknown status
Start date
December 31, 2016
Completion date
January 31, 2022
Enrollment
547 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia